Bioinformatics analysis of esophageal cancer unveils an integrated mRNA-lncRNA signature for predicting prognosis

Oncol Lett. 2020 Feb;19(2):1434-1442. doi: 10.3892/ol.2019.11208. Epub 2019 Dec 11.

Abstract

Esophageal cancer (ESCA) carries a poor prognosis among gastrointestinal malignancies. The present study developed a signature based on mRNAs and long non-coding RNAs (lncRNAs) to predict prognosis in ESCA by using The Cancer Genome Atlas database. By using least absolute shrinkage and selection operator penalized regression, a set of RNAs (three mRNAs and two lncRNAs) was identified and used to build a risk score system of ESCA prognosis, which was used to stratify patients having considerable diverse survival in the training set [hazard ratio (HR), 3.932; 95% CI, 1.555-9.944; P<0.002] into high- and low-risk groups. The authentication of the results was achieved through the test set (HR, 3.150; 95% CI, 1.113-8.918; P<0.02) and the entire set (HR, 3.181; 95% CI, 1.686-6.006; P<0.0002). The results from multivariate Cox proportional hazard regression analysis in the entire set suggested that the prognostic significance of this signature may be independent of patients' clinicopathological characteristics. Furthermore, this signature was associated with several molecular signaling pathways of cancer according to Gene Set Enrichment Analysis. In addition, a nomogram was built and the risk score and TNM stage were integrated to estimate the 1- and 3-year overall survival rates. The results from the present study demonstrated that the integrated mRNA-lncRNA signature may be considered as a novel biomarker for the prognosis of ESCA.

Keywords: The Cancer Genome Atlas; esophageal cancer; least absolute shrinkage and selection operator; prognostic signature.